[go: up one dir, main page]

MX2020004939A - Fabricacion de composiciones de celulas islote y metodos de uso de las mismas. - Google Patents

Fabricacion de composiciones de celulas islote y metodos de uso de las mismas.

Info

Publication number
MX2020004939A
MX2020004939A MX2020004939A MX2020004939A MX2020004939A MX 2020004939 A MX2020004939 A MX 2020004939A MX 2020004939 A MX2020004939 A MX 2020004939A MX 2020004939 A MX2020004939 A MX 2020004939A MX 2020004939 A MX2020004939 A MX 2020004939A
Authority
MX
Mexico
Prior art keywords
methods
islet cell
cell manufacturing
manufacturing compositions
compositions
Prior art date
Application number
MX2020004939A
Other languages
English (en)
Inventor
Felicia J Pagliuca
Austin Thiel
Jihad Yasin
Evrett Thompson
Original Assignee
Semma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semma Therapeutics Inc filed Critical Semma Therapeutics Inc
Publication of MX2020004939A publication Critical patent/MX2020004939A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/436—Inhibitors, antagonists of receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/23—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cells of the gastro-intestinal tract

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)

Abstract

En el presente documento se describen composiciones y métodos útiles para fabricar células SC-ß, y poblaciones aisladas de células SC-ß para su uso en diversas aplicaciones, tales como terapia celular.
MX2020004939A 2017-11-15 2018-11-15 Fabricacion de composiciones de celulas islote y metodos de uso de las mismas. MX2020004939A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762586808P 2017-11-15 2017-11-15
US201862669170P 2018-05-09 2018-05-09
PCT/US2018/061364 WO2019099725A1 (en) 2017-11-15 2018-11-15 Islet cell manufacturing compositions and methods of use

Publications (1)

Publication Number Publication Date
MX2020004939A true MX2020004939A (es) 2020-11-11

Family

ID=66539137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004939A MX2020004939A (es) 2017-11-15 2018-11-15 Fabricacion de composiciones de celulas islote y metodos de uso de las mismas.

Country Status (11)

Country Link
US (3) US11945795B2 (es)
EP (1) EP3710021A4 (es)
JP (2) JP7428653B2 (es)
KR (2) KR20250048146A (es)
CN (2) CN111630155B (es)
AU (2) AU2018370029B2 (es)
BR (1) BR112020009275A2 (es)
CA (1) CA3081762A1 (es)
IL (3) IL274436B2 (es)
MX (1) MX2020004939A (es)
WO (1) WO2019099725A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3638205A4 (en) 2017-06-14 2021-03-17 Semma Therapeutics, Inc. DEVICES AND METHODS FOR ADMINISTERING THERAPEUTICS
CA3081762A1 (en) 2017-11-15 2019-05-23 Semma Therapeutics, Inc. Islet cell manufacturing compositions and methods of use
EP3758719A4 (en) * 2018-03-02 2021-12-08 Vertex Pharmaceuticals Inc. METHODS FOR IMPROVING THE DIFFERENTIATION OF STEM CELLS INTO BETA CELLS
CA3108275A1 (en) 2018-08-10 2020-02-13 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
US12049645B2 (en) 2020-07-31 2024-07-30 Vertex Pharmaceuticals Incorporated Differentiation of pancreatic endocrine cells
CN113234664B (zh) * 2021-05-11 2024-05-10 澳门大学 一种胰腺祖细胞的制备方法及其应用
CA3232971A1 (en) 2021-11-01 2023-05-04 George Harb Stem cell derived pancreatic islet differentiation
WO2025117331A1 (en) 2023-12-01 2025-06-05 Eli Lilly And Company Methods of making stem cell-derived islet-like cells, as well as populations and compositions including the same
CN120813682A (zh) * 2024-02-09 2025-10-17 智新浩正(上海)医药科技有限公司 用于制备内胚层干细胞和由其衍生的胰岛的方法

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4391909A (en) 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4378016A (en) 1981-07-15 1983-03-29 Biotek, Inc. Artificial endocrine gland containing hormone-producing cells
US5425764A (en) 1992-07-30 1995-06-20 The University Of Toledo Bioartificial pancreas
US7153684B1 (en) 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US7018419B2 (en) 1994-05-20 2006-03-28 Spielberg Theodore E Microporous encapsulated endocrine cell disks, biconcave disks and multidimpled chambers for hormonal replacement
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
EP0822834A4 (en) 1995-04-07 2002-09-18 Einstein Coll Med RECOMBINANT (BETA) CELL AND ITS USE
US6051428A (en) 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6800480B1 (en) 1997-10-23 2004-10-05 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
EP1287116A2 (en) 2000-05-17 2003-03-05 Geron Corporation Neural progenitor cell populations
US7163918B2 (en) 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
ATE360063T1 (de) 2000-10-12 2007-05-15 Agency Science Tech & Res Nicht störendes, dreidimensionales system für die kultivierung und ernte verankerungsabhängiger zellen
AU9684401A (en) 2000-10-13 2002-04-22 Curis Inc Hedgehog antagonists, methods and uses related thereto
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
JP2005503759A (ja) 2001-01-24 2005-02-10 アメリカ合衆国 幹細胞の膵臓内分泌細胞への分化方法
WO2002092756A2 (en) 2001-05-15 2002-11-21 Rappaport Family Institute For Research In The Medical Sciences Insulin producing cells derived from human embryonic stem cells
CA2456981C (en) 2001-08-06 2012-02-28 Bresagen, Inc. Alternative compositions and methods for the culture of stem cells
JP2005506074A (ja) 2001-10-18 2005-03-03 イクシオン・バイオテクノロジー・インコーポレーテッド 肝臓の幹細胞および前駆細胞の膵臓機能細胞への転換
US20030077256A1 (en) 2001-10-19 2003-04-24 Paul Czernichow Pancreas regeneration using embryonic pancreatic cells
US7157278B2 (en) 2001-12-04 2007-01-02 Organogenesis, Inc. Cultured cells from pancreatic islets
IL162130A0 (en) 2001-12-07 2005-11-20 Robarts Res Inst Hematopoietic cells from human embryonic stem cells
IL162131A0 (en) 2001-12-07 2005-11-20 Geron Corp Islet cells from human embryonic stem cells
JP2005527241A (ja) 2002-05-28 2005-09-15 ベクトン・ディキンソン・アンド・カンパニー ｉｎｖｉｔｒｏにおけるヒト膵臓腺房細胞の増殖およびインスリン産生細胞への分化転換のための方法
AU2003240810A1 (en) 2002-05-28 2003-12-12 Becton, Dickinson And Company Methods, compositions, and growth and differentiation factors for insulin-producing cells
EP1567639A4 (en) 2002-12-05 2005-12-21 Technion Res & Dev Foundation CULTURE OF HUMAN PANCREATIC ISLANDS AND USES THEREOF
WO2004058764A1 (en) 2002-12-27 2004-07-15 Bayer Healthcare Ag 4-phenyl-pyrimido [4,5-b] indole derivatives
US7084246B2 (en) 2003-04-17 2006-08-01 Molecular Logix, Inc. Epidermal growth factor agonists
CA2549605C (en) 2003-12-23 2013-05-07 Cythera, Inc. Definitive endoderm
US7625753B2 (en) 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US7541185B2 (en) 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
WO2007059007A2 (en) 2005-11-14 2007-05-24 Cythera, Inc. Markers of definitive endoderm
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
EP2377922B1 (en) 2004-04-27 2020-04-08 Viacyte, Inc. PDX1 expressing endoderm
AU2005271723B2 (en) 2004-07-13 2010-12-16 Asterias Biotherapeutics, Inc. Medium for growing human embryonic stem cells
EP1791952A4 (en) 2004-08-13 2008-06-11 Univ Georgia Res Found COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS
US7517870B2 (en) 2004-12-03 2009-04-14 Fondazione Telethon Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
US20060194321A1 (en) 2005-01-31 2006-08-31 Alan Colman Directed differentiation of embryonic stem cells and uses thereof
CA2611809C (en) 2005-06-22 2018-06-19 Geron Corporation Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells
EP1910516B1 (en) 2005-06-22 2019-06-19 Asterias Biotherapeutics, Inc. Suspension culture of human embryonic stem cells
EP1957636B1 (en) 2005-10-27 2018-07-04 Viacyte, Inc. Pdx1-expressing dorsal and ventral foregut endoderm
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
JP5098028B2 (ja) 2005-12-13 2012-12-12 国立大学法人京都大学 核初期化因子
KR20080082618A (ko) 2005-12-16 2008-09-11 알콘, 인코퍼레이티드 Ａｌｋ5 조절제를 사용한 안압의 조절
WO2007075807A2 (en) 2005-12-20 2007-07-05 Es Cell International Pte Ltd. Methods for the directed differentiation of embryonic stem cell
DE602007011409D1 (de) 2006-01-20 2011-02-03 Reneuron Inc Verfahren für verbesserte zellproliferation von pankreas-vorläuferzellen in einer pankreaszellkultur
JPWO2007088651A1 (ja) 2006-02-01 2009-06-25 国立大学法人 東京大学 ＴＧＦ−βシグナル阻害剤と抗腫瘍剤の組み合せ使用
EP1989297B1 (en) 2006-02-13 2015-03-25 The Board of Trustees of The Leland Stanford Junior University Blockade of gamma-secretase activity to promote myelination by oligodendrocytes
AU2007220759A1 (en) 2006-02-23 2007-09-07 Viacyte, Inc. Compositions and methods useful for culturing differentiable cells
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
NZ571427A (en) 2006-03-02 2012-07-27 Viacyte Inc Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
WO2007109673A2 (en) 2006-03-20 2007-09-27 Stanford University Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor
EP2021462B1 (en) 2006-04-28 2019-01-09 Lifescan, Inc. Differentiation of human embryonic stem cells
US7964402B2 (en) 2006-05-25 2011-06-21 Sanford-Burnham Medical Research Institute Methods for culture and production of single cell populations of human embryonic stem cells
US8415153B2 (en) 2006-06-19 2013-04-09 Geron Corporation Differentiation and enrichment of islet-like cells from human pluripotent stem cells
AU2007277364B2 (en) 2006-07-26 2010-08-12 Viacyte, Inc. Methods of producing pancreatic hormones
PL2118309T3 (pl) 2006-12-29 2015-07-31 Univ Colorado Regents Cel diagnostyczny i terapeutyczny dla chorób autoimmunologicznych i jego zastosowania
DK2121905T3 (en) 2007-02-21 2016-05-17 Univercell Biosolutions HUMAN pancreatic beta-CELL LINES FOR DIAGNOSIS OF DIABETES
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
BRPI0814425A2 (pt) 2007-07-18 2014-10-21 Lifescan Inc Diferenciação de células-tronco embrionárias humanas
CN101952415B (zh) 2007-07-31 2017-06-27 生命扫描有限公司 人胚胎干细胞的分化
KR20100045458A (ko) 2007-08-09 2010-05-03 가부시끼가이샤 야구르트혼샤 신규 γ 세크레타아제 저해제
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8623650B2 (en) 2007-10-19 2014-01-07 Viacyte, Inc. Methods and compositions for feeder-free pluripotent stem cell media containing human serum
CA2706560C (en) 2007-11-27 2017-02-28 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
SG154367A1 (en) 2008-01-31 2009-08-28 Es Cell Int Pte Ltd Method of differentiating stem cells
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
DK2283117T3 (da) 2008-04-21 2014-01-20 Viacyte Inc Fremgangsmåde til oprensning af pancreatiske endodermceller afledt fra humane embryoniske stamceller
US8338170B2 (en) 2008-04-21 2012-12-25 Viacyte, Inc. Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells
US8728812B2 (en) 2008-04-22 2014-05-20 President And Fellows Of Harvard College Compositions and methods for promoting the generation of PDX1+ pancreatic cells
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US20090298178A1 (en) 2008-06-03 2009-12-03 D Amour Kevin Allen Growth factors for production of definitive endoderm
AU2009267137A1 (en) 2008-06-30 2010-01-07 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
US20110305672A1 (en) 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
US9683215B2 (en) 2008-08-22 2017-06-20 President And Fellows Of Harvard College Methods of reprogramming cells
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
JP2012507289A (ja) 2008-10-31 2012-03-29 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の膵内分泌系への分化
KR101712085B1 (ko) 2008-10-31 2017-03-03 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 췌장 내분비 계통으로의 분화
US8008075B2 (en) 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
EP3363444B1 (en) 2008-11-14 2022-09-14 ViaCyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
CA2744227C (en) 2008-11-20 2018-10-02 Centocor Ortho Biotech Inc. Methods and compositions for cell attachment and cultivation on planar substrates
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US20100267731A1 (en) 2009-04-17 2010-10-21 Summa Health Systems, LLC Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
SG175367A1 (en) 2009-04-27 2011-11-28 Viacyte Inc Small molecules supporting pluripotent cell growth and methods thereof
US9328331B2 (en) 2009-05-21 2016-05-03 Joslin Diabetes Center, Inc. Compositions and methods for promoting beta cell maturity
SG177483A1 (en) 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
SG177416A1 (en) 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
PH12012500818A1 (en) 2009-10-29 2019-11-29 Janssen Biotech Inc Pluripotent stem cells
KR101773538B1 (ko) 2009-12-23 2017-08-31 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
CN107189979B (zh) 2010-03-01 2021-05-04 詹森生物科技公司 纯化衍生自多能干细胞的细胞的方法
ES2624780T3 (es) 2010-03-31 2017-07-17 The Scripps Research Institute Reprogramación de células
WO2011128897A1 (en) 2010-04-12 2011-10-20 Technion Research & Development Foundation Ltd. Populations of pancreatic progenitor cells and methods of isolating and using same
EP2563908B1 (en) 2010-04-25 2019-01-09 Icahn School of Medicine at Mount Sinai Generation of anterior foregut endoderm from pluripotent cells
RU2663339C1 (ru) 2010-05-12 2018-08-03 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
AU2011290123B2 (en) 2010-08-09 2016-11-10 Takeda Pharmaceutical Company Limited Method of producing pancreatic hormone-producing cells
DK2603226T3 (da) 2010-08-12 2021-06-07 Janssen Biotech Inc Behandling af diabetes med endokrine pankreas-prækursorceller
GB201014169D0 (en) 2010-08-25 2010-10-06 Cambridge Entpr Ltd In vitro hepatic differentiation
WO2012030540A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
PH12013500367A1 (en) 2010-08-31 2013-04-01 Janssen Biotech Inc Differentiation of human embryonic stem cells
EP2853589B1 (en) 2010-08-31 2017-12-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US20120135015A1 (en) 2010-09-28 2012-05-31 Baylor Research Institute Induction of Pancreatic Stem Cells by Transient Overexpression of Reprogramming Factors and PDX1 Selection
US20120195401A1 (en) 2011-02-01 2012-08-02 Neal Becker System and method for correlating received signal over time and frequency
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013018851A1 (ja) 2011-08-02 2013-02-07 独立行政法人国立がん研究センター 誘導肝幹細胞から肝分化誘導する方法及び誘導肝前駆細胞
US20140243374A1 (en) 2011-10-04 2014-08-28 The Brigham And Women's Hospital, Inc. Novel Sulfonamides
ES2634457T3 (es) 2011-10-18 2017-09-27 Univercell Biosolutions Producción de una línea de células beta humanas a partir de un páncreas postnatal temprano
EP2776018B1 (en) 2011-11-13 2021-08-25 Cognitive Research Enterprises, Inc. Pkc activators and combinations thereof
SG11201403473QA (en) * 2011-12-22 2014-10-30 Janssen Biotech Inc Differentiation of human embryonic stem cells into single hormonal insulin positive cells
SI2844739T1 (sl) 2012-04-30 2019-11-29 Univ Health Network Postopki in sestavki za ustvarjanje pankreatičnih prednikov in funkcionalnih beta-celic iz hPSC-jev
AR090970A1 (es) 2012-05-07 2014-12-17 Janssen Biotech Inc Diferenciacion de celulas madre humanas embrionarias en endodermo pancreatico
ES2897649T3 (es) 2012-06-08 2022-03-02 Janssen Biotech Inc Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas
CA2876671A1 (en) 2012-06-14 2013-12-27 Janssen Biotech, Inc. Treatment of pluripotent cells
WO2014033322A1 (en) 2012-09-03 2014-03-06 Novo Nordisk A/S Generation of pancreatic endoderm from pluripotent stem cells using small molecules
US20150329821A1 (en) * 2012-10-19 2015-11-19 Agency For Science, Technology And Research Methods of differentiating stem cells into one or more cell lineages
DK2938723T3 (da) 2012-12-31 2023-02-20 Janssen Biotech Inc Differentiering af humane embryonale stamceller til pancreatiske endokrine celler under anvendelse af hb9-regulatorer
ES2837763T3 (es) 2012-12-31 2021-07-01 Janssen Biotech Inc Cultivo de células madre embrionarias humanas en la interconexión aire-líquido para la diferenciación en células endocrinas pancreáticas
HK1217727A1 (zh) 2012-12-31 2017-01-20 Janssen Biotech, Inc. 用於分化成胰腺內分泌細胞的人多能細胞的懸浮和群集
WO2014130887A1 (en) 2013-02-22 2014-08-28 Cedars-Sinai Medical Center Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells
US20140287944A1 (en) 2013-02-26 2014-09-25 President And Fellows Of Harvard College Markers for functionally mature beta-cells and methods of using the same
US10160950B2 (en) 2013-03-01 2018-12-25 Wisconsin Alumni Research Foundation Methods of maintaining, expanding and differentiating neuronal subtype specific progenitors
JP2016510745A (ja) * 2013-03-04 2016-04-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
US8859286B2 (en) * 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
CA2905993C (en) 2013-03-14 2022-12-06 Tolero Pharmaceuticals, Inc. Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
US20140329704A1 (en) 2013-03-28 2014-11-06 President And Fellows Of Harvard College Markers for mature beta-cells and methods of using the same
KR102523912B1 (ko) 2013-06-11 2023-04-21 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 SC-β 세포 및 조성물 그리고 그 생성 방법
WO2015028614A1 (en) 2013-08-30 2015-03-05 Novo Nordisk A/S Generation of endocrine progenitor cells from human pluripotent stem cells using small molecules
EP3143128A1 (en) 2014-05-14 2017-03-22 The University Court of The University of Aberdeen Methods of obtaining pancreatic endocrine cells
CN106414720A (zh) 2014-05-16 2017-02-15 詹森生物科技公司 小分子增强胰腺内分泌细胞中的mafa表达的用途
EP3149156B1 (en) 2014-05-28 2021-02-17 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10655105B2 (en) 2014-08-04 2020-05-19 Takeda Pharmaceutical Company Limited Method for proliferation of pancreatic progenitor cells
WO2016100925A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED β CELLS AND USES THEREOF
WO2016100921A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
WO2016100909A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
SG11201704961VA (en) * 2014-12-19 2017-07-28 Janssen Biotech Inc Suspension culturing of pluripotent stem cells
US9974784B2 (en) 2015-01-21 2018-05-22 The Texas A&M University System Inhibitors of activin-like receptor kinases
US10975355B2 (en) 2015-04-23 2021-04-13 The Regents Of The University Of California Controlled induction of human pancreatic progenitors produces functional beta-like cells
EP3328404A4 (en) 2015-07-27 2018-12-26 The Regents of The University of California Methods and compositions for producing pancreatic beta cells
WO2017091943A1 (en) 2015-11-30 2017-06-08 Hong Guan Ltd. Improved methods for reprograming non-pluripotent cells into pluripotent stem cells
EP3400286A1 (en) 2016-01-08 2018-11-14 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
MA45747A (fr) 2016-02-24 2019-01-02 Novo Nordisk As Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines
MA45329A (fr) * 2016-04-08 2019-02-13 Univ California Production de cellules bêta matures pleinement fonctionnelles à partir de progénitrices pancréatiques humaines
MA45502A (fr) 2016-06-21 2019-04-24 Janssen Biotech Inc Génération de cellules bêta fonctionnelles dérivées de cellules souches pluripotentes humaines ayant une respiration mitochondriale glucose-dépendante et une réponse en sécrétion d'insuline en deux phases
US20190390169A1 (en) * 2017-03-03 2019-12-26 Kyoto University Pancreatic progenitor cell production method
EP4488363A3 (en) 2017-07-21 2025-03-26 Vertex Pharmaceuticals Incorporated Re-aggregation of stem cell-derived pancreatic beta cells
CA3081762A1 (en) 2017-11-15 2019-05-23 Semma Therapeutics, Inc. Islet cell manufacturing compositions and methods of use
EP3758719A4 (en) 2018-03-02 2021-12-08 Vertex Pharmaceuticals Inc. METHODS FOR IMPROVING THE DIFFERENTIATION OF STEM CELLS INTO BETA CELLS
CA3101021A1 (en) 2018-05-31 2019-12-05 University Health Network Methods and compositions comprising tankyrase inhibitors for generating insulin producing cells
CA3108275A1 (en) 2018-08-10 2020-02-13 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
JP2022539169A (ja) 2019-06-25 2022-09-07 バーテックス ファーマシューティカルズ インコーポレイテッド ベータ細胞の分化の向上

Also Published As

Publication number Publication date
WO2019099725A1 (en) 2019-05-23
BR112020009275A2 (pt) 2020-10-27
IL274436B2 (en) 2024-01-01
AU2018370029B2 (en) 2024-11-07
IL274436A (en) 2020-06-30
IL312134A (en) 2024-06-01
EP3710021A1 (en) 2020-09-23
IL305391B2 (en) 2024-09-01
CN111630155B (zh) 2024-05-03
CN118497104A (zh) 2024-08-16
AU2024227349A1 (en) 2024-10-31
IL305391B1 (en) 2024-05-01
KR102789149B1 (ko) 2025-03-31
IL274436B1 (en) 2023-09-01
CN111630155A (zh) 2020-09-04
AU2018370029A1 (en) 2020-07-02
US20250376462A1 (en) 2025-12-11
IL305391A (en) 2023-10-01
US11945795B2 (en) 2024-04-02
KR20200087201A (ko) 2020-07-20
IL312134B1 (en) 2025-11-01
JP7428653B2 (ja) 2024-02-06
US20210017157A1 (en) 2021-01-21
CA3081762A1 (en) 2019-05-23
KR20250048146A (ko) 2025-04-07
US12304900B2 (en) 2025-05-20
US20240294501A1 (en) 2024-09-05
JP2024045311A (ja) 2024-04-02
JP2021502830A (ja) 2021-02-04
EP3710021A4 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
MX2020004939A (es) Fabricacion de composiciones de celulas islote y metodos de uso de las mismas.
CL2023000812A1 (es) Péptidos, combinaciones y andamiajes para uso en inmunoterapia contra el cáncer divisional de solic.2017-02448
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
MX2020004541A (es) Edicion de genes de celulas primarias.
CY1123823T1 (el) Βελτιωμενες συνθεσεις τ κυτταρων
CL2018002852A1 (es) Producción celular de ácido ribonucleico
CO2017013408A2 (es) Compuestos bicíclicos heterocíclicos como agentes antituberculares.
MX389749B (es) Sistemas y métodos para el uso simultáneo del espectro dentro del espectro usado activamente.
MX2020011254A (es) Celulas t car anti-bcma para agotamiento de celulas de plasma.
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
MX380204B (es) Micrordenamiento para suministro de agente terapeútico y métodos de uso.
UY35643A (es) Nuevos compuestos útiles como nematicidas, sus composiciones y métodos de uso
MX2019011570A (es) Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
BR112016030965A2 (pt) Composições de veículo-anticorpo e métodos de fabricação e uso das mesmas
EP4374863A3 (en) Methods for generating stem cell-derived beta cells and uses thereof
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR105602A1 (es) Medio de cultivo celular suplementado con taurina y métodos de utilización
MX373280B (es) Anticuerpos anti-egfrviii y usos de los mismos.
MX2017012206A (es) Proliferacion ex vivo de celulas epiteliales.
BR112019006865A2 (pt) caspases induzíveis e métodos para uso
MX2015012875A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
MX2021005395A (es) Terapia del cáncer con células inmunitarias anti-liv1.
CO2019009080A2 (es) Péptidos y métodos para el tratamiento de diabetes
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
WO2015041809A3 (en) Small molecule cellular reprogramming to generate neuronal cells